Search company, investor...

Founded Year

2002

Stage

Acq - P2P | Acquired

Total Raised

$75M

Valuation

$0000 

Revenue

$0000 

About Five Prime Therapeutics

Five Prime Therapeutics is a clinical-stage biotechnology company with a pipeline of antibodies and ligand traps for cancer, autoimmunity, and respiratory diseases. FivePrime has differentiated discovery capabilities built on its library of secreted and extracellular human proteins, which it leverages in cell-based assays, vivo models, and receptor-ligand matching screens to identify medically relevant new targets and therapeutic proteins. FivePrime has entered into a collaboration agreement to develop and commercialize its lead product, FP-1039 (HGS1036), with Human Genome Sciences in the United States, Canada, and the EU. FivePrime has also established collaborations for the discovery of biologics in specific therapeutic areas with several pharmaceutical companies, including Pfizer and Centocor. On April 16, 2021, Five Prime Therapeutics was acquired by Amgen.

Headquarters Location

111 Oyster Point Boulevard

South San Francisco, California, 94080,

United States

415-365-5600

Loading...

Loading...

Five Prime Therapeutics Patents

Five Prime Therapeutics has filed 116 patents.

The 3 most popular patent topics include:

  • clusters of differentiation
  • immune system
  • immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/10/2020

11/14/2023

Clusters of differentiation, Immune system, Immunology, Proteins, Peripheral membrane proteins

Grant

Application Date

3/10/2020

Grant Date

11/14/2023

Title

Related Topics

Clusters of differentiation, Immune system, Immunology, Proteins, Peripheral membrane proteins

Status

Grant

Latest Five Prime Therapeutics News

Amgen Completes Five Prime Therapeutics Deal

Apr 16, 2021

socaltech.com Amgen Completes Five Prime Therapeutics Deal Thousand Oaks-based Amgen said this morning that it has successfully completed its $1.9 billion acquisition of Five Prime Therapeutics, a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies. Amgen paid $38.00 per share in cash for Five Prime Therapeutics. Five Prime's programs include bemarituzumab, a Phase 3 trial-ready, first-in-class program for gastric cancer.

Five Prime Therapeutics Frequently Asked Questions (FAQ)

  • When was Five Prime Therapeutics founded?

    Five Prime Therapeutics was founded in 2002.

  • Where is Five Prime Therapeutics's headquarters?

    Five Prime Therapeutics's headquarters is located at 111 Oyster Point Boulevard, South San Francisco.

  • What is Five Prime Therapeutics's latest funding round?

    Five Prime Therapeutics's latest funding round is Acq - P2P.

  • How much did Five Prime Therapeutics raise?

    Five Prime Therapeutics raised a total of $75M.

  • Who are the investors of Five Prime Therapeutics?

    Investors of Five Prime Therapeutics include Amgen, GSK, National Multiple Sclerosis Society, Centocor, Pfizer and 17 more.

  • Who are Five Prime Therapeutics's competitors?

    Competitors of Five Prime Therapeutics include Forma Therapeutics, DiscoveryBioMed, IRX Therapeutics, BrightPath Biotherapeutics, Protagen and 7 more.

Loading...

Compare Five Prime Therapeutics to Competitors

W
Welichem Biotech

Welichem Biotech Inc. ("Welichem", TSX-V: WBI) is engaged in the discovery and development of small molecule therapeutics. Using its Symbiochem technology platform, the Company has developed a robust pipeline of patent-protected compounds that target autoimmune/inflammatory diseases and cancers. Welichem's lead drug candidate, WBI-1001, targets autoimmune/inflammatory skin disorders, such as psoriasis and eczema. A phase I clinical trial of WBI-1001, done in Montreal, in patients with psoriasis has shown a very good safety profile and promising efficacy. As well, the application of WBI-1001 cream against atopic dermatitis (a type of eczema) in a phase IIa clinical trial also has been completed in Canada, with the final report pending in the third quarter of 2008. Welichem plans to all the necessary Phase II Clinical Trials against psoriasis and eczema in the near future. In the company's pipeline, WBI-1001 related compounds are being evaluated also for their therapeutic potential against other autoimmune diseases such as, inflammatory bowel disease and rheumatoid arthritis. Welichem's other lead drug candidate, WBI-2100, selectively targets certain types of hard-to-treat cancerous tumours. This is achieved in part through inhibition of angiogenesis and metastasis. Animal tests have shown that WBI-2100 is effective as a monotherapy and also in increasing the effectiveness of several commonly used chemotherapeutic products. The uniqueness of this small molecule cancer chemotherapeutic is that in pre-clinical studies it increases the number of neutrophils in the peripheral blood. The boosting of neutrophils in animal studies in the presence of the cancer therapeutic, cyclophosphamide, supports its potential therapeutic application for chemotherapy induced neutropenia. With its proven Symbiochem; technology platform, Welichem will advance its pipeline of drug candidates at a rate and time commensurate with resources and target need, and is in a strong position to contribute effectively to productive drug discovery and development partnerships.

Proteintech Group Logo
Proteintech Group

Proteintech Group specializes in the production of antibodies and proteins, serving the biotechnology and pharmaceutical sectors. The company offers a wide range of products including polyclonal and monoclonal antibodies, immunoassay kits, and human cell-expressed cytokines and growth factors. Proteintech Group's offerings are utilized across various research areas such as cancer, immunology, and neuroscience. It is based in Chicago, Illinois.

A
Advanced Cancer Therapeutics

Advanced Cancer Therapeutics specializes in the biotechnology sector with a focus on developing novel cancer treatments. The company is engaged in the discovery and early development of new cancer therapeutics, and it facilitates the commercialization and manufacturing of promising discoveries. Advanced Cancer Therapeutics primarily serves the pharmaceutical industry by fast-tracking the development of cancer treatments from discovery to market. It was founded in 2007 and is based in Louisville, Kentucky.

Sentinel Oncology Logo
Sentinel Oncology

Sentinel Oncology is a small molecule drug discovery company focusing on the discovery and development of new chemical entities for the treatment of cancer.

V
VivoPath

VivoPath is a preclinical screening company, offering the company's clients discovery and development services for in vivo testing. VivoPath aims to provide integrated in vivo studies led by established experts in drug development. Efficacy is established for animal models in the areas of metabolic disease, inflammation, neurodegenerative disease, and infectious diseases. Formulation screening is carried out to select the most appropriate delivery system for administration. Pharmacokinetic evaluation is carried out to assess exposure and bioavailability. Tolerability is assessed with evaluations of clinical signs, clinical chemistry and hematology. The resulting program aims to deliver the client an in vivo therapeutic index (TI) report on which to assess candidates for subsequent development. VivoPath can also help clients at any individual step in this preclinical screening process. VivoPath's commitment is to provide scientific expertise in in vivo drug discovery in order to increase productivity from research into drug development.

A
Active Pass Pharmaceuticals

Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.